MINNEAPOLIS--(BUSINESS WIRE)--Data from the GuardControl Trial, the first international, large-scale, multi-center, randomized clinical outcome trial conducted to evaluate the use of Medtronic REAL-Time Continuous Glucose Monitoring (CGM) technology for improved diabetes management, was published today in Diabetes Care. The study demonstrated that patients using Medtronic REAL-Time CGM had better control of their blood glucose than patients using fingersticks only.
